IDRx is a clinical-stage biopharmaceutical company based in Plymouth, Massachusetts, focused on revolutionizing cancer treatment through precision combination therapies. Founded in 2022, IDRx aims to enhance patient outcomes with intelligently designed solutions tailored to target cancer more effectively.
National Ranking21215th
in United States Regional Ranking23136th
in North America Global Ranking57067th
worldwide Rankings by